AMRX vs LLY
As of Sep 20, 2026, Amneal Pharmaceuticals (AMRX) scores 6.9/10 and ELI LILLY (LLY) 7.2/10 on AlphaStocks' five-model composite, so LLY scores higher. AMRX trades 81% above its model fair value; LLY trades 76% above its model fair value.
AMRX
Amneal Pharmaceuticals, Inc.
6.9
Consider Buy
$18.70
LLY
ELI LILLY & Co
7.2
Consider Buy
$1,152.46
AMRX vs LLY: Which is the Better Investment?
Amneal Pharmaceuticals, Inc. (AMRX) scores 6.9/10 while ELI LILLY & Co (LLY) scores 7.2/10 on AlphaStocks' composite model. ELI LILLY & Co has the higher composite rating of Consider Buy. On a P/E basis, ELI LILLY & Co trades at 50.2x, making it the more attractively priced of the two.
This comparison is algorithmically generated and is not financial advice.
| Metric | AMRX | LLY |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 6.9/10 | 7.2/10▲ |
| Rating | Consider Buy | Consider Buy▲ |
| Price | $18.70 | $1,152.46 |
| P/E Ratio | 84.3 | 50.2▲ |
| ROE | -80.0% | 82.0%▲ |
| Market Cap | $6B | $1.0T |
| Fair Value | $10.31 | $656.48 |
| Dividend Yield | — | 0.5% |
| Sector Rank | #16 of 168 | #11 of 168▲ |
| Model Verdicts | ||
| Piotroski | Strong | Strong |
| Buffett | Neutral | Strong▲ |
| Graham | Neutral▲ | Caution |
| Lynch | Attractive▲ | Neutral |
| Greenblatt | Attractive▲ | Caution |
Related comparisons
AMRX vs LLY: Which Stock Scores Higher?
Amneal Pharmaceuticals, Inc. (AMRX) and ELI LILLY & Co (LLY) are both in the Health Care sector. LLY currently leads with a composite score of 7.2/10 (Consider Buy) compared to AMRX's 6.9/10 (Consider Buy).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer